Fuxia Li

628 total citations
14 papers, 150 citations indexed

About

Fuxia Li is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Fuxia Li has authored 14 papers receiving a total of 150 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Oncology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Fuxia Li's work include CRISPR and Genetic Engineering (3 papers), Renal and related cancers (2 papers) and PARP inhibition in cancer therapy (2 papers). Fuxia Li is often cited by papers focused on CRISPR and Genetic Engineering (3 papers), Renal and related cancers (2 papers) and PARP inhibition in cancer therapy (2 papers). Fuxia Li collaborates with scholars based in China and United States. Fuxia Li's co-authors include Rourou Xiao, Yuping Zhang, Qiongbo Hu, Yu Fu, Funian Lu, Zizhuo Wang, Chaoyang Sun, Ensong Guo, Wenting Li and Bin Yang and has published in prestigious journals such as Nature Communications, Cancer Research and PLoS Medicine.

In The Last Decade

Fuxia Li

14 papers receiving 149 citations

Peers

Fuxia Li
Comparison fields: 5 of 48
  • Molecular Biology 84
  • Oncology 63
  • Immunology 31
  • Insect Science 17
  • Pathology and Forensic Medicine 14
Replace Haocheng Wang with:
Haocheng Wang China
Ahmad Rajeh United States
Brendan Veeneman United States
Allison Kaeding United States
Zhili Jin China
Claire Buchta Rosean United States
Zhuang Jin China
Zizhuo Wang China
Weifang Zhu China
Otari Chipashvili United States
Haocheng Wang China View profile →
Citations per field, relative to Fuxia Li
Fuxia Li · 1×
Citations per year, relative to Fuxia Li
Fuxia Li · 1×

Countries citing papers authored by Fuxia Li

Since Specialization
Citations

This map shows the geographic impact of Fuxia Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fuxia Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fuxia Li more than expected).

Fields of papers citing papers by Fuxia Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fuxia Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fuxia Li. The network helps show where Fuxia Li may publish in the future.

Co-authorship network of co-authors of Fuxia Li

This figure shows the co-authorship network connecting the top 25 collaborators of Fuxia Li. A scholar is included among the top collaborators of Fuxia Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fuxia Li. Fuxia Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
# Work Indexed citations
1 1
2 14
3 8
4 5
5 1
6 38
7 1
8 3
9 5
10 17
11 20
12 3
13
mTOR inhibition overcomes primary and acquired resistance to Wee1 inhibition by augmenting replication stress in epithelial ovarian cancers.
14
14 20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026